ADAP Advocacy has publicly urged the Centers for Medicare and Medicaid Services (CMS) to exclude HIV antiretroviral therapies from the Medicare Drug Price Negotiation Program, citing significant risks to individuals with HIV/AIDS. The organization's comments emphasize the critical need for uninterrupted access to these medications to maintain viral suppression and prevent health complications.
Brandon M. Macsata, CEO of ADAP Advocacy, warned of the dire consequences of including HIV medications in the Negotiation Program. He pointed out that any disruption in treatment could lead to increased mortality rates and the development of drug-resistant HIV strains, undermining decades of progress in HIV treatment and prevention.
The advocacy group's stance is rooted in the 'treatment as prevention' strategy, which has been pivotal in reducing new HIV infections and associated healthcare costs. ADAP Advocacy's submission to CMS underscores the importance of safeguarding access to HIV medications to protect public health and sustain the advancements made in combating the HIV epidemic.
